CAMPINA NEDERLAND HOLDING B.V.
|CAMPINA NEDERLAND HOLDING B.V. Patent applications|
|Patent application number||Title||Published|
|20130096074||PROTEIN HYDROLYSATE ENRICHED IN PEPTIDES INHIBITING DPP-IV AND THEIR USE - Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an isolated peptide derivable from such a protein hydrolysate, or a mixture thereof, and the use of such protein hydrolysate or isolated peptide for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, in particular chosen from the group of obesity, type 2 diabetes mellitus and an immunological disorder.||04-18-2013|
|20100203026||PROBIOTICS FOR INDUCING SATIETY AND/OR SATIATION - The invention relates to the field of nutrition and medicine. Provided are compositions, bacterial strains and methods for inducing or enhancing satiety and satiation and for treating or preventing obesity, overweight and overweight related diseases.||08-12-2010|
|20100087549||EXTENDED RELEASE EXCIPIENT AND ITS USE - A controlled release excipient composition suitable in formulation of a slow or extended release tablet, contains a synergistic mixture of substantially uncross-linked carboxymethyl starch, or sodium starch glycolate (SSG), and a hydrophilic, non-ionic cellulose ether, preferably hydroxypropylmethylcellulose. Whether or not a SSG in the mixture is sufficiently uncross-linked in the context of the invention can be determined by sedimentation: 0.25 g of the formulation in 100 ml deionized water after 24 hours at 25° C., if subjected to centrifugation at 6080 G at 25° C. for 15 minutes, should exhibit a sedimentation volume of more than 60 ml.||04-08-2010|
|20100056458||Peptides Inhibiting Angiotensin-Converting Enzyme - The invention provides novel peptides having ACE-inhibiting properties derived from milk proteins, as well as their mixtures and their use as hypotensive aids. The peptides have from 2 up to 14 amino acid residues, at least one of which is a branched-chain amino acid. Examples include IV, LV, VLGPV, VPYPQ, VPYPQR, AVP, KIHP, KYKVPQL, FFVAPFPEVFG, VAPFPEVF, MKGLDI, KGLDI, LR, MHIRLS, MHI, IIA, IAEKT, LKALP, ALP and KK. The invention also provides a process of producing the peptide by enzymatic hydrolysis of milk proteins or other proteins.||03-04-2010|
|20090081308||ANHDYROUS LACTOSE AGGLOMERATES AND THE PREPARATION THEREOF - The invention relates to a process for the preparation of anhydrous lactose agglomerates, said process comprising (i) subjecting essentially anhydrous lactose primary particles comprising at least 60 wt % crystalline-lactose in a granulator to a wet granulation step at a temperature in the range of 30-100° C. using a binder solution, wherein the granulation mass is subjected to drying for at least part of the granulation step, and (ii) after-drying the granulation mass. The anhydrous lactose agglomerates thus produced comprise at least 50 wt %-lactose crystallites and have a total water content in the range of 0-1.0 wt %, which is required according to the standards laid down by the Pharmacopoeia for anhydrous lactose excipients. These agglomerates combine have excellent compactibility and flowability properties and are particularly useful as excipient in moisture-sensitive applications.||03-26-2009|
|20090075904||Protein Hydrolysate Enriched In Peptides Inhibiting DPP-IV And Their Use - Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an isolated peptide derivable from such a protein hydrolysate, or a mixture thereof, and the use of such protein hydrolysate or isolated peptide for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, in particular chosen from the group of obesity, type 2 diabetes mellitus and an immunological disorder.||03-19-2009|
|20090074893||Antiviral peptides - The invention provides a method for the prevention or treatment of virus infections comprising administering, to a human or animal individual susceptible to or suffering from a virus infection, an effective amount of one or more casein phosphopeptides (CPP). Also provided is a composition containing such casein peptides and further agents such as vitamin C and/or nutritional components for use in treating or preventing virus infections.||03-19-2009|
Patent applications by CAMPINA NEDERLAND HOLDING B.V.